Compare Koninklijke Philips NV (PHG) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Koninklijke Philips NV vs Spyre Therapeutics Inc. Common Stock — how do they compare? Koninklijke Philips NV trades at $25.18 (market cap $24.60B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Koninklijke Philips NV is far larger — about 3.3× Spyre Therapeutics Inc. Common Stock's market cap, and Koninklijke Philips NV pays a 4.05% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| PHG | SYRE | |
|---|---|---|
Market Cap | $24.60B | $7.35B |
Volume | 1,105,836 | 1,624,631 |
Sector | Health | Health |
52-Week High | $32.91 | $108.92 |
52-Week Low | $23.81 | $22.18 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $30.96B | $6.35B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.89, up 0.61% with a bullish technical signal despite mixed momentum indicators. The company shows strong earnings momentum with three consecutive quarterly beats and a return to profitability in 2025 after previous losses. Recent developments include new product launches in healthcare technology and a $33.7 million ARPA-H award for AI-enabled stroke care. Valuation metrics appear reasonable with P/E of 19.49 and P/S of 1.22.
The outlook remains cautiously optimistic with improving fundamentals but faces execution risks in a competitive healthcare technology market. Analyst consensus leans Hold (63.64%) with no Sell ratings, suggesting stable but not aggressive growth expectations. Key risks include cybersecurity vulnerabilities highlighted by recent hacking incidents and the need to maintain innovation leadership against larger competitors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
